JPMorgan Securities LLC recently announced the acquisition of new stake in Liminal BioSciences Inc. (NASDAQ:LMNL). This fresh investment now brings its stake to 0.00% valued currently at $1.0.
With over 0.22 million Liminal BioSciences Inc. (LMNL) shares trading Monday and a closing price of $0.41 on the day, the dollar volume was approximately $88297.59999999999. The shares have shown a negative half year performance of -4.63% and its price on 01/23/23 gained nearly 13.92%. Currently, there are 31.04M common shares owned by the public and among those 11.14M shares have been available to trade.
Insiders at the company have transacted a total of 11 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 9 of these insider trades were purchases, accounting for 31,706 shares. Insider sales of the common stock occurred on 2 occasions, with total insider shares sold totaling 609 shares.
Fidelity Nasdaq Composite Index F owns 22737.0 shares of the company’s stock, all valued at over $7390.0.
Shares of Liminal BioSciences Inc. (NASDAQ: LMNL) opened at $0.44, up $0.08 from a prior closing price of $0.36. However, the script later moved the day high at 0.4500, up 13.92%. The company’s stock has a 5-day price change of 10.09% and -27.42% over the past three months. LMNL shares are trading 26.18% year to date (YTD), with the 12-month market performance down to -58.99% lower. It has a 12-month low price of $0.31 and touched a high of $1.11 over the same period. LMNL has an average intraday trading volume of 25.37K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 14.53%, 0.25%, and -20.82% respectively.
Institutional ownership of Liminal BioSciences Inc. (NASDAQ: LMNL) shares accounts for 0.70% of the company’s 31.04M shares outstanding. Mutual fund holders own 0.07%, while other institutional holders and individual stakeholders account for 0.58% and — respectively.
It has a market capitalization of $12.76M and a beta (3y monthly) value of 1.17. The earnings-per-share (ttm) stands at -$0.73. The company has a debt-to-equity ratio at 0.04. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.27% over the week and 7.95% over the month.
Analysts forecast that Liminal BioSciences Inc. (LMNL) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and -$0.51 for 2023. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$0.54 a year ago. Earnings per share for the fiscal year are expected to increase by 25.40%, and -6.20% over the next financial year.
Piper Sandler coverage for the Liminal BioSciences Inc. (LMNL) stock in a research note released on June 02, 2021 offered a Neutral rating with a price target of $4.50. H.C. Wainwright was of a view on February 18, 2021 that the stock is Buy, while Piper Sandler gave the stock Overweight rating on December 21, 2020, issuing a price target of $22.